A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Chinese Patients With Advanced or Metastatic HR+/HER2- Breast Cancer and Other Solid Tumors
Latest Information Update: 07 Mar 2025
At a glance
- Drugs BGB-43395 (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors BeiGene
- 27 Feb 2025 According to a BeiGene media release, proof-of-concept data expected in the first half of 2025.
- 16 Apr 2024 Status changed from not yet recruiting to recruiting.
- 15 Feb 2024 New trial record